Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4 | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4	Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, central nervous system malformation, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, hereditary disease, hereditary sensory and autonomic neuropathy, inherited neurodegenerative disorder, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, peripheral nervous system disorder, polyneuropathy, uterine disorder	Not yet recruiting	Phase 2	2026-04-13		NCT07522697

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
National Cancer Institute, Naples	38

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
National Cancer Institute of Napoli, Division of Medical Oncology - Uro-Gynecology Department	Naples	Italy	1